Coffee: The Essential ‘Perk' Of A Perfect Hotel Or Resort Stay
When you wake up at the Montauk Yacht Club in the Hamptons, you can smell the rich aroma of the in-room machine brewing your morning cup of coffee.
On top of the minibar in every room, guests will find an espresso machine by Lavazza, the venerable, family-owned, Turin-based coffee company. A variety of coffee pods, filtered water, and eye-catching porcelain espresso cups accompany the service.
Sipping the coffee on your patio or deck with the sun beaming on the water, you might forget you are on Long Island and harken back to memories of a stay on the Italian Riviera.
Many cultures worldwide begin the day with a coffee ritual, whether at home or traveling. A 2025 report by the National Coffee Association (NCA) found that two-thirds of Americans drink at least one cup of coffee each day, with the average American coffee drinker consuming three.
Waking up to a disappointing cup of coffee at a luxury hotel or resort can leave a bad taste. Not just literally. It can also negatively affect a guest's overall impression of their stay.
The mere thought of enduring a week or more of watery, tasteless, or bitter coffee can be daunting. Negative comments slamming in-room coffee service abound on Reddit threads and Tripadvisor reviews.
'As I sit here in my room at…with my little cup of brown liquid that tastes of regret and despair, I wonder, 'Why do hotels even bother with this?' Hotel coffee sucks 95% of the time,' wrote one Reddit user.
The industry publication International Communicaffe found that two-thirds of consumers judge the quality of a hotel or restaurant based on the quality of their coffee. It can also affect rebooking decisions.
As coffee lovers become more knowledgeable and discerning about the sourcing, roasting, brewing, sustainability and taste of coffee, this creates pressure on the hospitality industry to meet their expectations.
As a result, hoteliers are upping their game when it comes to coffee service. The American Penchant For All Things Italian, Including Coffee
Vintage Vespa Scooter getty
Italy is renowned for its sophisticated style and taste, which permeate various aspects of its culture, including fashion, food, wine, and automobiles. This "Made in Italy" ethos also extends to its celebrated coffee culture.
Coffee in the Bel Paese has been an integral part of Italian life since the early 20th century. "Enjoying an espresso or cappuccino is not just a routine—it is a moment to slow down and savor," says Daniele Foti, Lavazza North American Marketing Vice President.
This sentiment, he says, encapsulates Lavazza's "La Dolce Vita" philosophy, which celebrates the beauty of everyday life found in small, intentional pleasures.
Looking at trends, the NCA report found that consumption of espresso-based beverages (which include cappuccinos, espressos, lattes, caffe mochas, macchiatos, flat whites and Americanos) increased by a whopping 17% from 2020 to 2025.
Foti believes that Americans are drawn to Italian coffee, not just for its quality and flavor, but also for the cultural experience it represents, which includes authenticity, simplicity, and connection. Lavazza: A Case Study of Italian Coffee's Hospitality Expansion
Lavazza Cafe at Montauk Yacht Club Lavazza
To expand its footprint in the U.S., Lavazza has been developing partnerships with properties and companies whose values resonate with those of the coffee maker.
Initial partners include the Four Seasons, Ennismore, Dinex Group, Paris Baguette, Eataly, Princess Cruises and high-profile events like the U.S. Open, Art Basel, Aspen One, and Taste of SLS.
Lavazza tailors its offerings to each partner from a menu that can include espresso-based beverages, cold brew, specialty drinks and brewed coffee made with Lavazza premium blends. They may even train baristas.
For example, at the Montauk Yacht Club, Lavazza designed a 360° coffee experience. Touchpoints at the resort include a branded cafe/market, in-room coffee kits, a poolside cart, and a custom Lavazza-infused dining and cocktail menu with items such as tiramisu, chilled mousse, and espresso martinis.
A Lavazza Tiramisu Martini Lavazza
Hotel Clio, a Luxury Collection Hotel in Denver's Cherry Creek section, also selected Lavazza as their preferred coffee source. 'The array of blends and single-origin coffees is among the best in the world in terms of flavor and consistency,' says Christopher Polys, Marketing Manager.
He explains that the Luxury Collection has its own Italian heritage, originating from the brand Compagnia Italiana Grandi Alberghi (CIGA). The Clio Hotel offers Lavazza in-room espresso and 24-hour drip in the lobby, using the Lavazza Crema line, which is suitable for classic on-the-go American coffees that use milk and sugar, he says.
Waking up at the Hotel Clio Denver Hotel Clio
The hotel's in-house restaurant, Toro by Chef Richard Sandoval, uses the Top Class line for desserts, like Toro's Mexican Affogato, and highlights the coffee with a complementary chocolate pairing at the hotel's 'Tuesday Epicurean Moments'. A Winning Marketing Strategy
Coffee at home getty
Hospitality partnerships like these upgrade the consumer coffee experience and, by association, simultaneously enhance the prestige of the property/company serving it.
'Guests in the luxury segment today expect excellence in the smallest details,' says Leah Miller, a marketing strategist with Versys Media. 'Coffee is no longer just a wake-up call; it's an aesthetic and sensory extension of the brand.'
The Italian ritual of stopping at a favorite bar before work for a quick espresso or cappuccino accompanied by a sweet pastry is still familiar in Italy. However, most coffee consumption in the U.S. and Italy takes place at home.
Lavazza's win-win hospitality partnerships also pay off in sales by introducing (or reintroducing) hotel and resort guests to its premium Italian coffee brand, which they can enjoy at home or away.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Motor 1
an hour ago
- Motor 1
Maserati Says People Have a 'Bad Feeling' About Electric Supercars
It's been a few months since Maserati canceled the fully electric MC20 after realizing customers 'are very keen on driving powerful ICE engines.' That's according to an official statement sent to Motor1 by a company spokesperson back in March. With that in mind, it's no surprise the Modena-based automaker is now channeling its efforts into gas-powered models. Davide Danesin, Head of Engineering, told Autocar that some people have a 'bad feeling' about supercars equipped with a battery. We'd add that the sentiment likely extends to most performance-oriented cars, from affordable hot hatches to seven-figure hypercars. He went on to admit that 'there are still customers looking for pure mechanical cars,' as evidencened by high-end buyers who had no interest in an EV version of the MC20. These concerns largely stem from the additional hardware EVs require, which increases complexity, adds weight, and introduces all the downsides that come with it. As a result, the plan is to give people what they want: a pure ICE experience via the company's Nettuno V-6. Beyond that, a manual gearbox could even make a surprising return. Maserati hasn't sold a three-pedal car since the mid-2000s. Yet, Danesin sees a stick shift as a real possibility for a limited-run model: 'By doing a purely mechanical car, it does make sense to have a mechanical gearbox with a shifter. It fulfils perfectly our approach and the mindset. So honestly, I think one day we'll do it.' Alfa Romeo and Maserati CEO Santo Ficili reiterates that the two Italian brands will collaborate more closely in the future, hinting at the prospect of a jointly developed gasoline supercar. The tie-up would follow the 33 Stradale, which partially borrowed the carbon tub and aluminum subframes at both ends from the MC20. Autocar speculates that a Maserati-branded supercar would likely be a Granturismo-based GT featuring an upgraded version of the twin-turbo 3.0-liter engine, delivering more than the 621 hp available in the MC20 and its MCPura successor. The added power would likely come without any electric assistance. An equivalent Alfa Romeo is reportedly also in the pipeline, helping to achieve economies of scale and make a solid business case. However, the brand's marketing boss, Cristiano Fiorio, recently said a follow-up to the 33 Stradale shouldn't be rushed, as volume-oriented models are the current priority . We shouldn't fault automakers for channeling resources into hybrids and EVs. Increasingly strict emissions regulations make it harder to justify investing in gas-powered sports cars, especially those with large-displacement engines. Another challenge facing car companies and their customers is the higher taxation on pure ICE vehicles in certain parts of the world, particularly in Europe. To give you a weird example: the BMW M3 is €17,350 ($20,000) more expensive than the M5 in Ireland, due to the latter's lower emissions (at least on paper) from its plug-in hybrid setup. Catch Up With Maserati: Maserati Is Not for Sale Maserati Sales Aren't Doing Great Source: Autocar Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Forbes
an hour ago
- Forbes
What Rome Teaches Us About Organizational Collapse
Organizational Collapse is a Behavioral Issue Standing in the ruins of the Roman Forum earlier this month, I wasn't thinking about emperors or empires. I was thinking about behavioral signaling. Rome was not just a political structure. It was a behavioral ecosystem that coordinated infrastructure, logistics, and governance across an astonishing geographic span. Its eventual unraveling was not the result of a single external shock. It was the gradual breakdown of coherence, purpose, and adaptive signaling. That is the biology of organizational collapse. Much like today's organizations, Rome scaled by shaping shared behaviors rather than managing every decision. And like many institutions now under pressure, it collapsed when those behavioral norms began to drift. Research in adaptive performance supports the idea that healthy systems evolve through tight feedback loops and behaviorally grounded coherence—not through rigid control. Cultural Norms and Organizational Collapse Rome's cohesion was driven not only by military power but by its ability to export shared norms. Law, language, ritual, and civic behavior allowed people across regions to operate within a common framework. These norms functioned like a behavioral operating system. In modern organizations, culture plays a similar role. It creates alignment without requiring constant oversight. When that alignment breaks down, confusion follows. Research on ritual and group cohesion shows that shared behaviors reduce conflict and increase cooperation. The erosion of those behaviors often marks the first phase of organizational collapse. Infrastructure Signals That Foreshadow Organizational Collapse The phrase 'All roads lead to Rome' wasn't just literal. Roads, aqueducts, and trade routes served as both physical and behavioral signals. They communicated stability, competence, and trust in the system. The same holds true for modern companies. Infrastructure like meeting rhythms, onboarding practices, decision protocols sends cues about what matters. In high-performing teams, those signals are intentional and aligned. In teams drifting toward dysfunction, infrastructure becomes erratic or symbolic rather than functional. As infrastructure decays, so does behavioral clarity. Bread, Circuses, and the Biology of Organizational Collapse Bread and Circuses Late-stage Rome turned to spectacle. Bread and circuses, free grain and gladiatorial games, were used to distract and pacify. What began as strategy became dysfunction. Over time, civic engagement was replaced by passive consumption. Organizations can fall into the same behavioral pattern. Perks and messaging may offer temporary lift, but when they substitute for meaning, they become distractions. Research on dopamine-driven reward cycles shows how short-term stimulation reduces long-term engagement. When the core purpose weakens, organizational collapse often follows behind the scenes. Over-Optimization Can Precede Organizational Collapse The Pax Romana offered peace and stability, but also led to over-centralization and stagnation. The system became optimized for efficiency rather than adaptability. When change came, the empire was brittle. Biological systems mirror this pattern. Monocultures perform well in controlled environments but fail under stress. Healthy ecosystems like and healthy organizations, build in complexity, redundancy, and flexibility. When everything is streamlined for speed or cost, resilience is sacrificed. What seems lean and effective may actually be vulnerable to collapse. Power Without Reciprocity and Organizational Collapse Rome transitioned from a participatory republic to an autocratic empire. As decision-making became concentrated, feedback loops weakened. Those in power stopped responding to the people they governed. Organizations face the same risk. As leadership structures flatten or centralize, they may become disconnected from the broader system. Studies in primate social structures show that dominance without reciprocity does not produce stable groups. In organizations, the absence of reciprocal trust leads to disconnection and decline. Once again, organizational collapse begins when behavioral cues no longer generate productive response. Organizational Collapse Starts From the Inside By the time foreign forces reached Rome's borders, the collapse had already begun. Corruption, disengagement, and elite disconnection weakened the system from within. The final blow was external, but the rot was internal. The same is true in companies. Competitor disruption or market crisis may appear to trigger failure, but in most cases, the signals had been pointing toward collapse for years. Strategic misalignment often begins with cultural drift, disengaged leadership, and incoherent infrastructure. From Collapse to Behavioral Repertoire Rome's story is more than history. It is a lesson in behavioral biology. Systems that rise through coherence fall when their signals fragment. Leaders today may not govern empires, but they do shape ecosystems of behavior. In my work helping leaders build behavioral fluency, I emphasize the importance of warmth, competence, and gravitas, three visible signals that allow others to interpret and respond. These are not traits; they are behaviors we can observe, tune, and strengthen. Organizational collapse is rarely sudden. It begins with subtle erosion. The most resilient leaders are those who invest in clarity of structural and behavioral signal long before failure is visible. Collapse is not inevitable. But coherence must be cultivated. From empire to team, it is the biology of behavior that holds systems together.
Yahoo
2 hours ago
- Yahoo
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
Alfasigma plans to submit data from the OLINGUITO Phase 3 clinical trial to European Medicines Agency (EMA) and UK's Medicines Healthcare products Regulatory Agency (MHRA) to seek market authorization for filgotinib in the treatment of adults with active axial spondyloarthritis (axSpA). Filgotinib, an oral, once-daily JAK1 preferential inhibitor, met the primary endpoint in the OLINGUITO Phase 3 clinical trial, demonstrating efficacy across the full spectrum of axSpA (r-axSpA and nr-axSpA). The safety profile was consistent with previous filgotinib studies, with no unexpected events observed. AxSpA is a chronic inflammatory disease primarily affecting young adults, typically emerging during the third decade of life, with only 40-50% of patients with axSpA achieving adequate response with current treatments. If approved, filgotinib would offer a new oral treatment option for patients with axSpA expanding the treatment landscape in a therapeutic area marked by significant unmet needs. BOLOGNA, Italy, July 28, 2025--(BUSINESS WIRE)--Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),i evaluating filgotinib (marketed as Jyseleca® in approved indications) to treat adult patients with active axial spondyloarthritis (axSpA). Filgotinib, an oral, once-daily JAK1 preferential inhibitor, met the primary endpoint in the OLINGUITO Phase 3 clinical trial in active axSpA. Efficacy was demonstrated across the full spectrum of axSpA, including both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms. The safety profile was consistent with previous studies, with no unexpected events Filgotinib is currently approved for the treatment of moderate to severe active rheumatoid arthritis (RA) and ulcerative colitis (UC).iii "These positive OLINGUITO topline results demonstrate filgotinib's potential to address this critical unmet need for patients with axial spondyloarthritis, with only half responding adequately to current therapies," said Daniele D'Ambrosio, Chief Development Officer at Alfasigma. "Based on these encouraging results, we intend to submit for an extension of filgotinib's current indications, offering a potential new treatment option for patients with axial spondyloarthritis who often struggle with debilitating symptoms from a young age. We thank all patients, investigators and staff at study sites whose participation made this important achievement possible." "These results from the OLINGUITO Phase 3 clinical trial clearly support the potential of filgotinib as a treatment option for patients living with axSpA at all stages of the disease. The burden of disease for these patients remains high as treatment options are limited. It is therefore encouraging that the primary endpoint for both axSpA indications was met in dedicated studies," said Professor Xenofon Baraliakos, Head of Rheumatology at the Rheumazentrum Ruhrgebiet, Herne, Germany, Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany. AxSpA is a chronic inflammatory disease primarily affecting young adults, typically emerging during the third decade of life. It primarily affects the axial skeleton (spine and sacroiliac joints) causing significant pain, stiffness and reduced Despite several efficacious anti-inflammatory treatment options, only about 40% to 50% of patients with axSpA achieve a relevant treatment response, and an even smaller proportion (approximately 10%-20%) reach remission or an inactive disease activity state within 16 to 24 weeks of treatment initiation.v About OLINGUITO The OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01) was designed – in compliance with the European Medicines Agency's (EMA) guidelines – to evaluate the efficacy and safety of filgotinib in patients with active axial spondyloarthritis (axSpA). OLINGUITO was preceded by the TORTUGA Phase 2 clinical trial (NCT03117270), a randomized, double-blind, placebo-controlled clinical trial that demonstrated the safety and efficacy of filgotinib in adult patients with moderately to severely active ankylosing spondylitis (also known as r-axSpA, i.e., the damage caused by the disease can be seen on X-rays).vi The first patient entered the OLINGUITO Phase 3 clinical trial in April 2023. The trial consisted of two randomized, double-blind, multi-center, parallel-group studies of patients with active axSpA who had an inadequate response to conventional or biological treatments. Study A included 258 patients with r-axSpA, while study B included 237 patients with non-radiographic axSpA (nr-axSpA, i.e., the patient had symptoms of axSpA but damage was not yet visible on X-rays). After enrollment, patients in each study were randomized (1:1) to receive treatment with oral filgotinib 200 mg, or matching placebo, once daily for 16 weeks. The primary endpoint for both studies was the proportion of patients who achieved an Assessment of SpondyloArthritis international Society 40% improvement (ASAS40) at Week Thereafter, patients without risk factors entered an open-label treatment period in which they received filgotinib 200 mg once daily up to Week 52. Patients from study A and study B who achieved sustained low disease activity or inactive disease during the open-label period were re-randomized (1:1) at Week 52 to receive double-blind filgotinib 100 mg or 200 mg up to Week 104. In patients above 65 years of age and those with increased risk factors for cardiovascular disease or malignancies, at Week 16 in the case of achievement of disease control after treatment with 200 mg once daily, the dose was reduced to 100 mg once daily for up to Week 104. All patients receiving filgotinib 100 mg daily had the option to increase to 200 mg daily in case of flares. Week 52 visits for all patients were completed in May 2025. After Week 104, select eligible patients who achieve ASAS40 response without high disease activity, per investigators' judgment, will enter the Open Label Extension (OLE) study. This OLE is designed to collect additional long-term safety and efficacy data for a duration of approximately 2.5 years. About Filgotinib Filgotinib (marketed as Jyseleca®) is currently approved by the relevant regulatory authorities in the European Union, United Kingdom, Japan, Taiwan, South Korea and Singapore. In Europe, United Kingdom, Japan, Taiwan, South Korea and Singapore, filgotinib is approved for the treatment of moderate to severe active rheumatoid arthritis in adults who have not responded adequately or cannot tolerate other disease modifying anti-rheumatic drugs (DMARDs). Filgotinib is also approved in Europe, United Kingdom, Japan Taiwan, South Korea and Singapore for the treatment of adult patients with moderate to severe active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib 100mg and 200mg are registered in the above-mentioned territories. The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at The United Kingdom Summary of Product Characteristics for filgotinib can be found at The interview form from the Japanese Ministry of Health, Labor and Welfare is available at The Taiwan Food and Drug Administration Assessment Report for filgotinib can be found at The Korean Ministry of Food and Drug Safety report on filgotinib can be found here The Singapore Summary of Product Characteristics for filgotinib can be found at About axial spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that primarily affects the axial skeleton (spine and sacroiliac joints). While persistent back pain and spinal stiffness are common initial symptoms, the disease often also presents with peripheral manifestations such as enthesitis, arthritis, and dactylitis, as well as extra-musculoskeletal features including uveitis, inflammatory bowel disease and psoriasis. AxSpA comprises the whole spectrum of patients with and without radiographic sacroiliitis, that is, radiographic axSpA (r-axSpA; also known as ankylosing spondylitis, i.e., the damage caused by the disease can be seen on X-rays) and non-radiographic axSpA (nr-axSpA), respectively. AxSpA usually starts during the third decade of life; r-axSpA is more common in men than women, whereas there is an equal sex distribution among patients with About Alfasigma Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered (in Bologna and Milan). The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. It has offices in several countries, including Italy, the US, Spain, Germany, Mexico, and China; production sites in Italy (Pomezia, RM; Alanno, PE; Sermoneta, LT; Trezzano Rosa, MI), Spain (Tortosa, Baix Ebre), and the United States (Shreveport, Louisiana); and R&D labs in Italy (Pomezia and Bergamo). Alfasigma employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products, contributing to its mission, to provide better health and a better quality of life for patients, caregivers, and healthcare providers'. It focuses on three main therapeutic areas: Gastroenterology, Vascular and Rheumatology. Its portfolio spans from primary care to specialty care, rare disease medications, and consumer health products, including medical foods and nutraceuticals. For more information, please visit Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Alfasigma. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. Alfasigma assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References i OLINGUITO Clinical Trial (NCT05785611) Study Details | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | Accessed July 2025. ii The topline results of OLINGUITO Phase 3 clinical trial will become available in future scientific conferences and published in a peer-reviewed journal in due course. iii Accessed July 2025. iv Navarro-Compán V, et al., Axial spondyloarthritis. Lancet 2025; 405: 159–72 v Poddubnyy D, et al. Ann Rheum Dis 2025; 84(4): 538-546. doi: 10.1016/ vi Van der Heijde D, et al. Lancet 2018; 392(10162): 2378-2387. doi: 10.1016/S0140-6736(18)32463-2 vii J. Sieper, et al. Ann Rheum Dis. 2009 Jun:68 Suppl 2:ii1-44. doi: 10.1136/ard.2008.104018. Based on the ASAS (Assessment of SpondyloArthritis International Society) assessment that includes four aspects (domains): patient global assessment, pain, function and inflammation. In order to meet ASAS40 response, 3 of the 4 domains should improve by at least 40% with a minimum 2-unit change on a scale of 0 to 10. For the remaining domain, there should be no deterioration (worsening) from baseline. View source version on Contacts Contact Press Office:Gea Annie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
